Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.48 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2059178 | 1.00 | SIRT2 (0.48) | SIRT2ATMTRPM8L3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL5574076 | 0.99 | SIRT2 (0.48) | SIRT2ATMTRPM8L3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL28584081 | 0.99 | SIRT2 (0.48) | SIRT2ATMTRPM8L3MBTL1MEN1 | |
| Hydrochloric Acid SCHEMBL6506712 | 0.99 | SIRT2 (0.48) | SIRT2ATMTRPM8L3MBTL1MEN1 | |
| SCHEMBL27786110 | 0.89 | MAPT (0.47) | TRPM8MEN1KMT2AALDH1A1ITGA4 | |
| SCHEMBL1643961 | 0.87 | GAA (0.40) | ALDH1A1MAPT | |
| SCHEMBL466340 | 0.87 | GAA (0.40) | ALDH1A1MAPT | |
| SCHEMBL466341 | 0.87 | GAA (0.40) | ALDH1A1MAPT | |
| SCHEMBL3339240 | 0.87 | ROCK2 (0.39) | SIRT2L3MBTL1ITGA4ITGB7MAPT | |
| SCHEMBL10448518 | 0.86 | ALDH1A1 (0.39) | SIRT2ATMTRPM8ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257028-A1 | Method for selectively binding a substrate to sorbents by way of at least bivalent bonds | INSTRACTION GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| US-20110257028-A1 | Method for selectively binding a substrate to sorbents by way of at least bivalent bonds | INSTRACTION GMBH (DE) | 2011-10-20 | — | — | US | disclosed |
| EP-1001764-A4 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1001764-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | Merck & Co., Inc. (a New Jersey corp.) (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1998053814-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS CELL ADHESION INHIBITORS | MERCK & CO., INC. (US) | 1998-12-03 | — | — | WO | disclosed |
| WO-1989004835-A1 | HUMAN RESPIRATORY SYNCYTIALVIRUS VACCINE DERIVED FROM THE 1A (9.5 kD) PROTEIN | THE UPJOHN COMPANY (US) | 1989-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257028-A1 | Method for selectively binding a substrate to sorbents by way of at least bivalent bonds | SPR, ABCG2, SHBG | SIRT2 1820/4885ATM 4670/4885TRPM8 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.